Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 6Other solid neoplasm 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 9Breast Neoplasms 8Carcinoma, Non-Small-Cell Lung 6Melanoma 4Head and Neck Neoplasms 4Ovarian Neoplasms 3Carcinoma, Renal Cell 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Neoplasms 1Mesothelioma, Malignant 1Lung Neoplasms 1Hypersensitivity 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1Breast Cancer Early Stage Breast Cancer (Stage 1-3) 1

Interventions

pembrolizumab 14Gemcitabine 8Docetaxel 7Nivolumab 6durvalumab 5Cyclophosphamide 5130-nm albumin-bound paclitaxel 5atezolizumab 4Magnetic Resonance Spectroscopy 4Irinotecan 4sargramostim 3aldesleukin 3Specimen Handling 3Radiotherapy 3Paclitaxel 3Ipilimumab 3Fulvestrant 3Cisplatin 3Carboplatin 3venetoclax 2temsirolimus 2talazoparib 2spartalizumab 2olaparib 2liposomal doxorubicin 2fludarabine phosphate 2cabozantinib 2budigalimab 2avelumab 2Vinorelbine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × Immune Checkpoint Inhibitors × Breast × Clear all
NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Jules Bordet Institute

Phase 2 Unknown
441 enrolled
BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡